ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Merck & Co., Inc. securities between February 3, 2022, and February 3, 2025, of the April 14, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Merck securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2025 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that throughout the Class Period, Merck provided investors with optimistic revenue expectations of $11 billion from Gardasil sales by 2030 while concealing adverse facts about demand in China [4] - Defendants reportedly made materially false and misleading statements regarding Gardasil's demand, leading to inflated inventory levels for its distributor, Zhifei [4]